trending Market Intelligence /marketintelligence/en/news-insights/trending/nRrsLYOFQCzFDNZueLZWZA2 content esgSubNav
In This List

Yunnan Hongxiang Q2 profit climbs 63.0% YOY

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Earnings forecasts for US banks; corporate deleveraging; LatAm currency gains

Blog

Insight Weekly: M&A slows down; climate tops proxy season; private equity pours into blockchain


Yunnan Hongxiang Q2 profit climbs 63.0% YOY

Yunnan Hongxiang Yixintang Pharmaceutical Co. Ltd. said its normalized net income for the second quarter was 14 fen per share, an increase of 63.2% from 8 fen per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 70.9 million yuan, an increase of 63.0% from 43.5 million yuan in the prior-year period.

The normalized profit margin climbed to 4.9% from 3.4% in the year-earlier period.

Total revenue climbed 13.4% year over year to 1.47 billion yuan from 1.30 billion yuan, and total operating expenses climbed 9.9% on an annual basis to 1.35 billion yuan from 1.23 billion yuan.

Reported net income increased 8.6% year over year to 90.6 million yuan, or 17 fen per share, from 83.4 million yuan, or 16 fen per share.

As of Aug. 15, US$1 was equivalent to 6.64 yuan.